tmo11kfisherplan2008.htm
 


 
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549
____________________________________________________

FORM 11-K

FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS AND SIMILAR PLANS
PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

(mark one)
[ X ]
Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 for the Fiscal Year Ended December 31, 2008

[     ]
Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934

Commission File Number 1-8002

THERMO FISHER SCIENTIFIC INC. 401(K) RETIREMENT PLAN

                A.  
Full title of the plan and address of the plan, if different from that of the issuer named below:

Thermo Fisher Scientific Inc. 401(k) Retirement Plan

                B.  
Name of issuer of the securities held pursuant to the plan and the address of the principal executive office:

Thermo Fisher Scientific Inc.
81 Wyman Street
Waltham, Massachusetts 02451





 
 

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
December 31, 2008 and 2007 


Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed by the undersigned hereunto duly authorized.
 
                       THERMO FISHER SCIENTIFIC INC. 401(k) RETIREMENT PLAN
 
                       By:  Thermo Fisher Scientific Inc., Pension Committee


              By:   /s/ Peter M. Wilver                                                            
 
                     Peter M. Wilver
 
                     Senior Vice President, Chief Financial Officer and
 
                     Member of the Pension Committee
 
Date:  June 24, 2009

 
 

 

Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Financial Statements and Supplemental Schedules
December 31, 2008 and 2007
 
 
 
 
 
 
 


 
 

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Index

   
Page(s)
     
Report of Independent Registered Public Accounting Firm
 
1
     
Financial Statements
   
     
      Statements of Net Assets Available for Benefits at December 31, 2008 and 2007
 
2
     
Statement of Changes in Net Assets Available for Benefits for the Year Ended December 31, 2008
 
3
     
Notes to Financial Statements
 
4-10
     
Supplemental Schedules*
   
     
Schedule H, Line 4i – Schedule of Assets (Held at End of Year)
 
11
     
      Schedule H, Line 4a – Schedule of Delinquent Participant Contributions  
12

*
Other supplemental schedules required by Section 2520.103.10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure
under the Employee Retirement Income Security Act of 1974 have been omitted because they are not applicable.


 
 

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
 

Report of Independent Registered Public Accounting Firm

To the Participants and Administrator of Thermo Fisher Scientific Inc. 401(k) Retirement Plan
and the Pension Committee of Thermo Fisher Scientific Inc.

 
In our opinion, the accompanying statements of net assets available for benefits and the related statement of changes in net assets available for benefits present fairly, in all material respects, the net assets available for benefits of Thermo Fisher Scientific Inc. 401(k) Retirement Plan (the “Plan”) at December 31, 2008 and 2007, and the changes in net assets available for benefits for the year ended December 31, 2008 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
 
Our audits were conducted for the purpose of forming an opinion on the basic financial statements taken as a whole. The supplemental schedules of Schedule H, Line 4i – Schedule of Assets (Held at End of Year) and Schedule H, Line 4a – Schedule of Delinquent Participant Contributions are presented for the purpose of additional analysis and are not a required part of the basic financial statements but are supplementary information required by the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. These supplemental schedules are the responsibility of the Plan’s management. The supplemental schedules have been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, are fairly stated in all material respects in relation to the basic financial statements taken as a whole.

PricewaterhouseCoopers LLP

Boston, Massachusetts
June 23, 2009



 
1

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Statements of Net Assets Available for Benefits
December 31, 2008 and 2007

(In thousands)
 
2008
 
2007
 
           
Assets
         
Investments, at fair value
  $ 811,647   $ 1,103,554  
Loans to participants, at fair value
    19,489     16,520  
               
      831,136     1,120,074  
               
Receivables
             
      Due from Lancaster Laboratories 401(k) Incentive Savings Plan
        39,878  
      Employer contributions
    1,647     698  
      Participant contributions
    117     310  
               
      1,764     40,886  
               
Liabilities
             
Corrective distributions payable
    191      
               
            Net assets available for benefits at fair value
    832,709     1,160,960  
               
            Adjustment from fair value to contract value for collective trust investments in fully benefit-responsive investment contracts
    765     (242 )
               
            Net assets available for benefits
  $ 833,474   $ 1,160,718  



 






The accompanying notes are an integral part of these financial statements.

 
2

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Statement of Changes in Net Assets Available for Benefits
For the Year Ended December 31, 2008

(In thousands)
 
2008
 
       
Additions
     
      Investment income (loss)
     
            Dividends and interest income
  $ 45,949  
 Net depreciation in fair value of investments
    (425,103 )
         
                  Total investment loss, net
    (379,154 )
         
Contributions
       
 Employer
    53,584  
 Participants
    76,642  
 Participant rollover
    9,600  
         
                  Total contributions
    139,826  
         
                  Total reductions, net
    (239,328 )
         
Deductions
       
      Benefits paid to participants
    87,797  
      Administrative expenses
    119  
         
                  Total deductions
    87,916  
         
Net decrease in net assets available for benefits
    (327,244 )
         
Net Assets Available for Benefits
       
      Beginning of year
    1,160,718  
         
      End of year
  $ 833,474  





 



The accompanying notes are an integral part of these financial statements.

 
3

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Notes to Financial Statements
For the Year Ended December 31, 2008

Note 1.      Plan Description

The following description of the Thermo Fisher Scientific Inc. 401(k) Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General and Plan Mergers

The Plan is a defined contribution plan. In November 2006, Thermo Electron Corporation (the “Original Plan Sponsor”) and Fisher Scientific International Inc. merged creating a new combined entity, Thermo Fisher Scientific Inc. (the “Plan Sponsor”, the “Company”). The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”).

The following defined contribution plans of the Company were merged into the Thermo Fisher Scientific Inc. Choice Plan effective on December 31, 2007: the Fisher Scientific International Inc. Savings and Profit Sharing Plan (the “Fisher plan”), the Athena Diagnostics, Inc. Employees Savings Trust (the “Athena plan”) and the Lancaster Laboratories 401(k) Incentive Savings Plan (the “Lancaster plan”). As of December 31, 2007, the net assets of the Athena Plan were held by MG Trust Company and the net assets of the Lancaster plan were held by The Vanguard Group, Inc., which were the respective trustees. The transfers of those assets to T. Rowe Price Trust Company, the trustee as defined by the Plan at December 31, 2007, occurred in January 2008. T. Rowe Price Trust Company replaced Fidelity Management Trust Company (“Fidelity”), as trustee of the Plan effective December 28, 2007. Effective January 1, 2008, in a Plan amendment, the merged plan was renamed the Thermo Fisher Scientific Inc. 401(k) Retirement Plan.

Eligibility

Before the merger, participation in the Plan was limited to eligible full-time and part-time employees of the Original Plan Sponsor who had completed two months of service. Each eligible employee who was a participant in the Thermo Fisher Scientific Inc. Choice Plan or the Fisher plan, Athena plan, or Lancaster plan on the day before the Plan amendment dated January 1, 2008, continues as a participant in the merged plan as amended. Any other eligible employee who is employed by the Company on and after January 1, 2008, becomes a participant on their date of hire.

Contributions

Each year participants may contribute on a pre-tax basis up to 50% of their eligible compensation, not to exceed the limits of the Internal Revenue Code. Participants may also contribute amounts representing distributions from other qualified defined benefit or defined contribution plans. Effective January 1, 2008, the Company’s non-discretionary matching contribution is equal to 100% of the first 6% of eligible compensation that a participant contributes to the Plan. Participants direct the investment of their contributions and the Company match into various investment options offered by the Plan. The Plan offers the Company’s common stock and twenty investment funds. Contributions are subject to certain limitations. Employee contributions and Company match are recorded on a bi-weekly basis or weekly for those employees on a weekly payroll.

Participant Accounts

Each participant’s account is credited with the participant’s contributions, the Company match, income or losses on those balances, as well as withdrawals, loan fees and loan repayments, as applicable.

 
4

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Notes to Financial Statements
For the Year Ended December 31, 2008

Administrative Expenses

The Company pays certain administrative expenses associated with the management of and professional services provided to the Plan. Administrative fees for hardship withdrawals and loan transactions are paid by the participants, and are included in the Statement of Changes in Net Assets Available for Benefits.

Vesting

Participants are immediately vested in both their voluntary contributions and the Company contributions plus actual income or losses on those balances.

Participant Loans

Beginning January 1, 2008, participants may borrow from both the employee and employer portions of their accounts. Loans must be for a minimum of $1,000 and have a maximum equal to $50,000 or 50% of the vested account balance, whichever is less. The term of the loan is generally five years except when use of the proceeds is for the purchase of a primary residence, for which the term can be up to 30 years. The loans are secured by the balance in the participant’s account and bear interest set at the prime rate as established in the Wall Street Journal, plus 1%. The prime rate and rate of interest on new Plan loans are determined as of the beginning of each calendar month. The interest rates on existing loans range from 4% to 11.5% at December 31, 2008 and 2007. Principal and interest are repaid through payroll deductions.

Benefit Payments and Plan Withdrawals

Upon termination of service due to death, disability or retirement, a participant (or beneficiary) may elect to receive either a lump-sum amount equal to the value of the participant’s vested interest in his or her account or periodic installments. For termination of service due to other reasons, a participant may receive the value of the vested interest in his or her account as a lump-sum distribution. Withdrawals may be made under certain other circumstances in accordance with the Plan document.

Forfeitures

Forfeitures that exist in the Plan were either introduced into the Plan as a result of the mergers described above or were created in previous years before vesting in Company contributions was immediate. All participant accounts in the Plan were 100% vested as of January 1, 2008.

Previously, forfeitures were used to reduce the Company’s future funding requirements. Effective January 1, 2008, forfeitures are used to pay Plan expenses. In 2008, expenses of $58,000 were paid from forfeited nonvested accounts. At December 31, 2008 and 2007, there was $774,000 and $795,000, respectively, in accumulated forfeitures available to pay Plan expenses in the future.

Note 2.      Summary of Significant Accounting Policies

Use of Estimates

The financial statements of the Plan are prepared on the accrual basis of accounting. The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and changes therein, and the disclosures of contingent assets and liabilities. Actual results could differ from those estimates.

 
5

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Notes to Financial Statements
For the Year Ended December 31, 2008

Investment Valuation and Income Recognition

Investments are stated at fair value. Shares of mutual funds are valued at quoted market prices, which represent the net asset value at year end. The Plan’s interests in collective trusts are valued based on the fair value and contract value of the underlying investments of those funds or trusts. The Company’s common stock is valued based on quoted market prices. Participant loans are valued at cost plus accrued interest, which approximates fair value. Refer to Note 5 for more information on valuation of the Plan’s investments.

Purchases and sales of investments are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date.

In the Statement of Changes in Net Assets Available for Benefits, the Plan presents the net depreciation in the fair value of its investments, which consists of realized gains or losses and unrealized appreciation (depreciation) on investments. The cost of investments is determined using the average-cost basis for calculating realized gains or losses.

As described in Financial Accounting Standards Board Staff Position, FSP AAG INV-1 and SOP 94-4-1, Reporting of Fully Benefit-Responsive Investment Contracts Held by Certain Investment Companies Subject to the AICPA Investment Company Guide and Defined-Contribution Health and Welfare and Pension Plans (the FSP), investment contracts held by a defined-contribution plan are required to be reported at fair value. However, contract value is the relevant measurement attribute for that portion of the net assets available for benefits of a defined-contribution plan attributable to fully benefit-responsive investment contracts because contract value is the amount participants would receive if they were to initiate permitted transactions under the terms of the Plan. The Plan invests in investment contracts through collective trusts. As required by the FSP, the Statements of Net Assets Available for Benefits presents the fair value of the investments in the collective trusts as well as the adjustments of the investments in the collective trusts from fair value to contract value relating to the investment contracts. The Statement of Changes in Net Assets Available for Benefits is prepared on a contract value basis.

Payment of Benefits

Benefits are recorded when paid.
 
Risks and Uncertainties

The Plan invests in various investment securities, including mutual funds and investment contracts, which are exposed to various risks, such as interest rate, credit and overall market volatility. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in the value of investment securities, it is at least reasonably possible that changes in values of investment securities will occur in the near term and that such changes could materially affect the participants’ account balances and the amounts reported in the Statement of Net Assets Available for Benefits.

Note 3.      Tax Status

The Plan has received a favorable determination letter dated February 4, 2009, from the Internal Revenue Service. The Plan has been amended since applying for the determination letter; however, the Plan administrator, management and the Plan’s tax counsel believe that the Plan has been designed and operated in compliance with the applicable requirements of the Internal Revenue Code.


 
6

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Notes to Financial Statements
For the Year Ended December 31, 2008

Note 4.      Investments

Investments of the Plan’s net assets are as follows:

   
December 31,
 
(In thousands)
 
2008
 
2007
 
           
Mutual Funds
         
      T. Rowe Price Retirement 2020 Fund (1)(2)
  $ 115,876   $ 156,044  
T. Rowe Price Retirement 2025 Fund (1)(2)
    97,103     132,301  
T. Rowe Price Retirement 2015 Fund (1)(2)
    95,113     120,728  
T. Rowe Price Retirement 2030 Fund (1)(2)
    78,286     104,554  
T. Rowe Price Retirement 2010 Fund (1)(2)
    59,429     74,528  
T. Rowe Price Retirement 2035 Fund (1)
    42,916     57,044  
Dodge & Cox International Stock Fund (2)
    39,544     60,395  
Dodge & Cox Stock Fund
    31,188     41,208  
T. Rowe Price Retirement 2040 Fund
    28,162     33,392  
Vanguard Mid Capitalization Index Fund, Instl.
    20,084     25,401  
Western Asset Core Plus Bond Fund, Instl.
    19,128     14,332  
T. Rowe Price Retirement 2005 Fund
    18,257     18,897  
T. Rowe Price Retirement Income Fund
    13,112     12,004  
T. Rowe Price Retirement 2045 Fund
    9,867     9,727  
T. Rowe Price Retirement 2050 Fund
    2,215     1,295  
T. Rowe Price Retirement 2055 Fund
    1,181     1,295  
Van Kampen Fund Class A
        1,565  
Lord Abbett Mid-Cap Value Fund
        742  
Columbia Acorn Fund Class A
        605  
Van Kampen Growth and Income Fund
        545  
American Funds Amcap Fund Class A
        502  
Van Kampen Equity Income Fund
        501  
American Funds Investment Co of America
        391  
Munder Index 500 Fund Class A
        388  
AIM Mid-Cap Core Equity Fund
        387  
Munder Small-Cap Value Fund Class A
        364  
AIM International Growth Fund
        323  
Eaton Vance Govt Obligations Fund
        320  
Munder Mid-Cap Core Growth Fund
        301  
Columbia Federal Securities Fund Class A
        282  
Templeton Foreign Fund Class R
        264  
Pioneer High Yield Fund Class A
        196  
Franklin Small-Cap Value Fund
        154  
Nationwide U.S. Growth Leaders Fund Class A
        92  
Franklin Templeton Moderate Target Fund
        85  
Franklin Templeton Conservative Target Fund
        42  
Fidelity Advisor Equity Growth Fund
        2  

 
7

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Notes to Financial Statements
For the Year Ended December 31, 2008

   
December 31,
 
(In thousands)
 
2008
 
2007
 
           
Common Collective Trusts
         
T. Rowe Price Stable Value Fund (1)(2)
  $ 81,667   $ 104,841  
Fidelity Managed Income Portfolio II: Class II
        49,836  
SSGA S&P 500 Index Fund
    18,174     21,821  
T. Rowe Price Growth Stock Trust
    12,563     17,580  
Jennison Institutional U.S. Small-Cap Equity Fund
    11,352     15,060  
               
Common Stock
             
Thermo Fisher Scientific Inc., 482,250 and 402,573 shares, respectively
    16,430     23,220  
               
Total Investments, at Fair Value
  $ 811,647   $ 1,103,554  

(1) Investment represents five percent or more of the Plan’s net assets at December 31, 2008.
(2) Investment represents five percent or more of the Plan’s net assets at December 31, 2007.

During 2008, the Plan’s investments (including investments bought, sold and held during the year) depreciated in value by $425,103,000, as follows:

(In thousands)
 
Year Ended
December 31,
2008
 
       
Mutual Funds
  $ 389,001  
Common Collective Trusts
    25,226  
Common Stock
    10,876  
         
Net Decrease in Fair Value
  $ 425,103  

Dividends and interest income of $45,949,000 consisted of the following for the year ended December 31, 2008:

(In thousands)
 
Year Ended
December 31,
2008
 
       
Mutual Funds
  $ 39,703  
Common Collective Trusts
    4,914  
Participant Loans
    1,332  
         
Dividends and Interest Income
  $ 45,949  


 
8

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Notes to Financial Statements
For the Year Ended December 31, 2008

Note 5.      Fair Value Measurements

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements.” SFAS No. 157 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. This statement applies to other accounting pronouncements that require or permit fair value measurements. This statement does not require any new fair value measurements. On January 1, 2008, the Plan adopted SFAS No. 157.

SFAS No. 157 requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities that the Company has the ability to access.

Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates, and yield curves.

Level 3: Inputs are unobservable data points that are not corroborated by market data.

The asset’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The following table presents information about the Plan’s financial assets measured at fair value on a recurring basis as of December 31, 2008:

(In thousands)
 
December 31,
2008
 
Quoted
Prices in
Active Markets
(Level 1)
 
Significant
Other
Observable
Inputs
(Level 2)
 
Significant
Unobservable
Inputs
(Level 3)
 
                   
Assets
                 
      Mutual funds
  $ 671,461   $ 671,461   $   $  
  Common collective trusts
    123,756         123,756      
  Common stock
    16,430     16,430          
  Participant loans
    19,489             19,489  
                           
            Total assets at fair value
  $ 831,136   $ 687,891   $ 123,756   $ 19,489  

The following table is a rollforward of the fair value of Level 3 assets for the year ended December 31, 2008:

(In thousands)
 
Participant
Loans
 
       
Balance at December 31, 2007
  $ 16,520  
      Issuances, repayments and settlements, net
    2,551  
      Loans transferred in from the Lancaster plan
    418  
         
Balance at December 31, 2008
  $ 19,489  

 
9

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Notes to Financial Statements
For the Year Ended December 31, 2008

Note 6.      Related-party Transactions
 
            Certain Plan investments are shares of mutual funds or interests in common collective trusts that were managed by Fidelity, which was the trustee as defined by the Plan during 2007, and T. Rowe Price Retirement Services, an affiliate of T. Rowe Price Trust Company, the trustee as defined by the Plan since the end of 2007. Therefore, transactions in these investments, including dividend and interest earned of $38,240,000, qualify as party-in-interest transactions. Fees paid by the Plan for investment management services were included as a reduction of the return earned on each fund. Participant loans also qualify as party-in-interest transactions. Interest on participant loans, which is included in interest and dividends on the Statement of Changes in Net Assets Available for Benefits, was $1,332,000 in 2008.
 
            The Plan invests in common stock of the Company and transactions in this common stock are related-party transactions. In 2008 and 2007, the Plan purchased shares of Company common stock on the open market having a value of $8,207,000 and $865,000, respectively. In 2008 and 2007, the Plan sold shares of Company common stock on the open market having values of $4,121,000 and $3,131,000, respectively.

Note 7.      Plan Termination
 
            Although it has not expressed an intention to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan, subject to the provisions of ERISA. In such event, the assets of the Plan would be distributed to participants in accordance with plan provisions.

 
10

 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Schedule H, Line 4i
Schedule of Assets (Held at End of Year)
December 31, 2008                                                                              Supplemental Schedule
 
 
Identity of Issue/Borrower,
Lessor or Similar Party
 
Description of investments including maturity date,
rate of interest, collateral, par, or maturity value
 
Cost
 
Current Value
(In thousands)
 
               
Mutual Funds
             
T. Rowe Price
 
T. Rowe Price Retirement 2020 Fund (1)
 
(2)
  $ 115,876  
T. Rowe Price
 
T. Rowe Price Retirement 2025 Fund (1)
 
(2)
    97,103  
T. Rowe Price  
T. Rowe Price Retirement 2015 Fund (1)
 
(2)
    95,113  
T. Rowe Price
 
T. Rowe Price Retirement 2030 Fund (1)
 
(2)
    78,286  
T. Rowe Price
 
T. Rowe Price Retirement 2010 Fund (1)
 
(2)
    59,429  
T. Rowe Price
 
T. Rowe Price Retirement 2035 Fund (1)
 
(2)
    42,916  
Dodge & Cox
 
Dodge & Cox International Stock Fund
 
(2)
    39,544  
Dodge & Cox
 
Dodge & Cox Stock Fund
 
(2)
    31,188  
T. Rowe Price
 
T. Rowe Price Retirement 2040 Fund (1)
 
(2)
    28,162  
Vanguard
 
Vanguard Mid Capitalization Index Fund, Instl. (1)
 
(2)
    20,084  
Western Asset Management Company
 
Western Asset Core Plus Bond Fund, Instl.
 
(2)
    19,128  
T. Rowe Price
 
T. Rowe Price Retirement 2005 Fund (1)
 
(2)
    18,257  
T. Rowe Price
 
T. Rowe Price Retirement Income Fund (1)
 
(2)
    13,112  
T. Rowe Price
 
T. Rowe Price Retirement 2045 Fund (1)
 
(2)
    9,867  
T. Rowe Price
  T. Rowe Price Retirement 2050 Fund (1)  
(2)
    2,215  
T. Rowe Price
 
T. Rowe Price Retirement 2055 Fund (1)
 
(2)
    1,181  
               
   
Total mutual funds
        671,461  
                 
Common Collective Trusts
               
T. Rowe Price
 
T. Rowe Price Stable Value Fund (1)
 
(2)
    82,432  
State Street Global Advisors
 
SSGA S&P 500 Index Fund
 
(2)
    18,174  
T. Rowe Price
 
T. Rowe Price Growth Stock Trust (1)
 
(2)
    12,563  
Jennison Associates
 
Jennison Institutional U.S. Small-Cap Equity Fund
 
(2)
    11,352  
                 
   
Total common collective trusts
        124,521  
                 
Common Stock
               
Thermo Fisher Scientific Inc.
 
Common stock (1)
 
(2)
    16,430  
                 
                 
Participant Loans
 
Participant loans (for a term not exceeding 30 years at interest rates ranging from 4.0% to 11.5%) (1)
 
(2)
    19,489  
                 
   
Total
      $ 831,901  
 
(1)
Investments are a party-in-interest to the Plan.
(2)
Cost information is not required for participant directed investments and, therefore, is not included.

 

 
11

 
 
 
Thermo Fisher Scientific Inc. 401(k) Retirement Plan
Schedule H, Line 4a - Schedule of Delinquent Participant Contributions
December 31, 2008                                                                              Supplemental Schedule
 

                       Participant Contributions
                     Transferred Late to the Plan
 
Amounts that Constitute
Nonexempt Transactions
(In thousands)
 
       
Participant contributions withheld on 1/31/2008 (Athena)*,
3/20/2008 (Matrix)*, 4/11/2008 (4640SID Commercial) and
10/12/2008 (4640SID Commercial)
 
$53
 

*Represents late contributions for which Form 5330 has been filed and excise taxes have been paid prior to December 31, 2008. The Plan will complete the
  filing and pay the excise taxes for the remaining late contributions.

 

 
12

 


Exhibit
Number                   Description of Exhibit 


   23.1                      Consent of PricewaterhouseCoopers LLP.




 
13